193738-16-8

Upstream product

• 699-83-2 2,6-dihydroxylacetophenone 
• 96-32-2 bromoacetic acid methyl ester 
• 96-34-4 methyl chloroacetate 

Downstream Products

• 770745-68-1 4-(2-carboxyethyl)-2'-(carboxymethoxy)-6'-hydroxydihydrochalcone 
• 193738-54-4 3-Methyl-4-(4-trifluoromethyl-benzyloxy)-benzofuran-2-carboxylic acid methyl ester 
• 193738-55-5 3-Methyl-4-(4-nitro-benzyloxy)-benzofuran-2-carboxylic acid methyl ester 
• 193738-58-8 4-(2-Methoxy-benzyloxy)-3-methyl-benzofuran-2-carboxylic acid methyl ester 
• 193738-59-9 4-(3,4-Dimethoxy-benzyloxy)-3-methyl-benzofuran-2-carboxylic acid methyl ester 
• 193738-60-2 4-(3,5-Dimethoxy-benzyloxy)-3-methyl-benzofuran-2-carboxylic acid methyl ester 
• 193738-51-1 4-(4-Carboxy-benzyloxy)-3-methyl-benzofuran-2-carboxylic acid methyl ester 
• 193738-57-7 4-(3-Methoxy-benzyloxy)-3-methyl-benzofuran-2-carboxylic acid methyl ester 
• 193738-49-7 4-(3-Chloro-benzyloxy)-3-methyl-benzofuran-2-carboxylic acid methyl ester 
• 193738-50-0 4-(3,4-Dichloro-benzyloxy)-3-methyl-benzofuran-2-carboxylic acid methyl ester 
• 193738-56-6 4-(4-methoxybenzyloxy)-3-methylbenzofuran-2-carboxylic acid, methyl ester 
• 193738-52-2 4-(4-Cyano-benzyloxy)-3-methyl-benzofuran-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AND THEIR USE

The present invention provides compounds of the general formula (I) or a pharmaceutically acceptable prodrugs, salts and/or solvates thereof, wherein LHS is selected from the group consisting of LHSa and LHSb And wherein, the asterisk (*) marks the point of attachment; These compounds exhibit antibacterial activity against Gram-negative and Gram-positive bacteria, especially S. aureus, E. coli, K. pneumoniae and A. baumannii. Pharmaceutical compositions containing these compounds, therapeutic uses thereof and methods for manufacturing the same are also provided.

Synthesis and in vitro analysis of novel dihydroxyacetophenone derivatives with antimicrobial and antitumor activities

Herein we report a feasible study concerning the design, syntheses and in vitro antimicrobial and antitumoral activities of some novel compounds with dihydroxyacetophenone (DA) moiety. An efficient and general method for the preparation of diazine with dihydroxyacetophenone (DDA) skeleton under conventional thermal heating (TH), microwave (MW) and ultrasounds (US) irradiation is presented. Antimicrobial and antitumoral tests prove that some dihydroxyacetophenone compounds (the brominated derivatives BrDA 3) have a significant biological activity. It is also to be pointed out that, basically all the dihydroxyacetophenone derivatives proved to have a powerful antibacterial activity against drug resistant Gram-negative strain Pseudomonas aeruginosa ATCC 27853. Of particular interest could be the excellent antibacterial activity of our dihydroxyacetophenone compounds against drug resistant Gram-negative strain Pseudomonas aeruginosa.

FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF

The present invention provides fused heterocyclic derivatives represented by the general formula: wherein R1 represents H, halogen, OH, etc.; R2 represents H, halogen or an alkyl group; R3 and R4 represent H, OH, halogen, etc.; Q represents alkylene, etc.; ring A represents aryl or heteroaryl; and G represents or ???or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

Benzofuran derivatives as ET(A)-selective, non-peptide endothelin antagonists

The synthesis and SAR relationships of a series of 4-benzyloxy-3-methylbenzofuran-2-carboxylic acids are described. Compounds from this series show 2- to 16-fold selective binding to the ET(A) receptor in the micromolar range, and two compounds from this series (32 and 40) were demonstrated to exhibit ET(A) antagonist activity.